OSUR
SellHot AirOraSure Technologies, Inc. · Healthcare · United States · $248M · Avg Vol: $2M/d
Hot Air: Rising on momentum alone: weak business, rich price.
ABOUT ORASURE TECHNOLOGIES, INC.
Read
OraSure Technologies, Inc. develops, manufactures, and markets a broad range of diagnostic products and collection devices, primarily focused on oral fluid technology for infectious diseases like HIV and COVID-19, and substance abuse. The company holds a competitive edge through its proprietary oral fluid collection platforms and established market presence in point-of-care diagnostics, catering to both clinical and consumer markets.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 387.5M | 405.5M | 185.8M | 115.0M | -33.3% | 112.4M | 122.1M | 133.2M | 7.6% |
| EPS | -0.25 | 0.73 | -0.26 | -0.94 | — | -0.69 | -0.80 | -0.66 | — |
| Shares | 72.7M | 73.5M | 74.6M | 70.4M | -3.2% | 69.0M | — | — | — |
| Debt | 12.5M | 13.5M | 14.6M | 13.2M | 1.7% | 12.1M | — | — | — |
| Equity | 364.4M | 430.7M | 410.3M | 340.8M | -2.2% | — | — | — | — |
| Op CF | -47.2M | 141.6M | 27.4M | -49.0M | -80.7% | -42.9M | — | — | — |
| Inv CF | 21.1M | 66.2M | -39.0M | -6.8M | — | — | — | — | — |
| Fin CF | -3.8M | -3.0M | -4.2M | -16.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OSUR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| OSUR | OraSure Technologies, Inc.(you) | $248M | 33 | Sell |
| KRMD | KORU Medical Systems, Inc. | $148M | 25 | Sell |
| ANGO | AngioDynamics, Inc. | $655M | 52 | Hold |
| STXS | Stereotaxis, Inc. | $145M | 5 | Strong Sell |
| SMTI | Sanara MedTech Inc. | $318M | 68 | Buy |
| KMTS | Kestra Medical Technologies, Ltd. | $1.5B | 26 | Sell |
| DXR | Daxor Corporation | $60M | 50 | Hold |
| AZTA | Azenta, Inc. | $1.4B | 46 | Hold |
| WRBY | Warby Parker Inc. | $3.1B | 34 | Sell |
| STAA | STAAR Surgical Company | $1.1B | 57 | Hold |
Peer medians: ROE -31.0% · P/E 25.1x · Gross margin 58.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.